DBV Technologies | Income Statement

Fiscal year is January-December. All values EUR Thousands.
2013
2014
2015
2016
2017
2018
Sales/Revenue
181.80
210.80
202.00
-
-
4,212
Cost of Goods Sold (COGS) incl. D&A
392.80
602.50
1,201.00
1,349.00
2,926.00
4,212
Gross Income
211.00
391.70
999.00
1,349.00
2,926.00
4,212
SG&A Expense
23,385.90
28,794.90
50,511.00
123,766.00
153,967.00
176,527
EBIT
23,264.80
29,186.60
51,510.00
124,812.00
156,893.00
180,739
Non Operating Income/Expense
670.20
938.40
1,297.00
3,069.00
3,196.00
3,995
Interest Expense
24.30
103.20
146.00
16.00
3,325.00
351
Pretax Income
22,618.90
28,351.50
50,359.00
121,759.00
157,022.00
177,095
Income Tax
3,312.50
4,339.60
5,685.00
7,228.00
9,329.00
11,019
Consolidated Net Income
19,306.40
24,011.90
44,674.00
114,531.00
147,693.00
166,076
Net Income
19,306.40
24,011.90
44,674.00
114,531.00
147,693.00
166,076
Net Income After Extraordinaries
19,306.40
24,011.90
44,674.00
114,531.00
147,693.00
166,076
Net Income Available to Common
19,306.40
24,011.90
44,674.00
114,531.00
147,693.00
166,076
EPS (Basic)
1.42
1.49
2.08
4.68
5.97
5.74
Basic Shares Outstanding
13,604.70
16,086.20
21,522.30
24,454.90
24,757.20
28,925
EPS (Diluted)
1.42
1.49
2.08
4.68
5.97
5.74
Diluted Shares Outstanding
13,604.70
16,086.20
21,522.30
24,454.90
24,757.20
28,925
EBITDA
22,923.60
28,671.30
50,437.00
123,463.00
153,967.00
176,527
Other Operating Expense
332.10
-
-
303.00
-
-

About DBV Technologies

View Profile
Address
177-181, avenue Pierre Brossolette
Montrouge Ile-de-France 92120
France
Employees -
Website http://www.dbv-technologies.com
Updated 07/08/2019
DBV Technologies SA is a clinical-stage biopharmaceutical company, which deals with conducting of research and development of epicutaneous immunotherapy products. It focuses on developing a novel technology platform called Viaskin, which is an electrostatic patch that offers a convenient, self-administered, non-invasive immunotherapy to patients. The company has designed two products candidates: Viaskin Peanut and Viaskin Milk.